Cantor Fitzgerald Downgrades Hyperion Therapeutics (HPTX) to Hold Amid Takeover Deal
Tweet Send to a Friend
Cantor Fitzgerald downgraded Hyperion Therapeutics (NASDAQ: HPTX) from Buy to Hold with a price target of $46.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
